Atopic Dermatitis
Conference Coverage
No lab monitoring needed in adolescents on dupilumab
Reassuring safety results from LIBERTY AD PED-OLE, an open-label extension study.
From the Journals
Baricitinib reduces adult atopic dermatitis severity in phase 3 study
In moderate to evere AD, baricitinib 4 mg on top of topical corticosteroids significantly reduced signs and symptoms.
Photo Challenge
Irritable Baby With Weight Loss and a Periorificial and Truncal Rash
A 4-month-old infant boy presented to the pediatric hospital unit with a rash, fever, and failure to thrive. Prior to admission, the patient was...
Commentary
Active Comparator Trial Designs Used to Promote Development of Innovative New Medications
Although some recent clinical trials in dermatology have included active comparators, many new medications continue to be introduced without any...
Latest News
EMA panel backs baricitinib for moderate to severe atopic dermatitis
If approved in Europe, it will be the first Janus kinase inhibitor and first oral medication indicated to treat patients with AD.
Conference Coverage
Three-step approach may help relieve one of the itchiest vulvar conditions
Treatment of lichen simplex chronicus should aim to optimize epithelial barrier function, reduce inflammation, and stop scratching.
Commentary
Filling Gaps: Moving Toward Better Treatment of Children With Atopic Dermatitis
It is a brand-new day for the treatment of children with severe inflammatory skin diseases. Not coincidentally, it also is a new day for the...
Clinical Review
Update on Pediatric Atopic Dermatitis
There has been tremendous growth in our understanding of atopic dermatitis, with further insight into epidemiology, the impact on quality of life...
Case Reports
Cutaneous T-cell Lymphoma and Concomitant Atopic Dermatitis Responding to Dupilumab
Dupilumab has offered promising results in atopic dermatitis (AD) treatment; however, concerns exist that its use may exacerbate undiagnosed...
Case Reports
Long-standing Dermatitis Treated With Dupilumab With Subsequent Progression to Cutaneous T-cell Lymphoma
Following off-label treatment with dupilumab, 3 patients with long-standing eczematous or psoriasiform dermatitis had clinical expansion of...
From the Journals
Large study finds no link between TCI use, skin cancer in patients with AD
“Controversy has surrounded the association between TCI exposure and KC risk since the black-box warning was issued by the FDA.”